IBBQ News and Press, Invesco Nasdaq Biotechnology ETF From 06/25/22

The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...

Invesco Nasdaq Biotechnology ETF (IBBQ) - $0.0426. 30-Day SEC Yield of 0.71% as of June 17. Payable June 30; for shareholders of record June 22; ex-div June 21. For further details see: Invesco Nasdaq Biotechnology ETF declares quarterly distribution of $0.0426

How similar will the next three or five years look from the years that immediately preceded the pandemic? And what are the implications for us as global equity investors? We don’t expect anything like the hyperinflation and stagflation we experienced in the 1970s; our outlook s...

Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock’s expected coming price range limits. By comparing today’s balance of upside and downside price change p...

With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...

Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...

We circle back on OncoCyte Corp. for the first time in just over one year. This oncology diagnostic concern has several new products it plans to launch on the near-term horizon. A beneficial owner was a heavy buyer of a recent secondary offering. A full investment analysis is prov...

AMTI is developing a medicine for pouchitis. The company is undercovered and maybe undervalued. Its drug delivery platform is its key asset. For further details see: Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...

Historically, RYH has generated a return in the range of 14 to 24 percent. As an equal weight healthcare ETF, returns of RYH are less volatile. RYH’s price multiples and SMAs indicate a possible overvaluation. For further details see: RYH: Equal Weight Healthcare ...